[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"total-hip-replacement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:total-hip-replacement":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,58,91,124,148,175,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370",false,"NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",true,"ALL","18 Years","80 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Pain Management","Pain","Nav 1.8","JOURNAVX","Opioid Cessation","Opioid Consumption, Postoperative","Multimodal Analgesia","Randomized Controlled Trial","Randomized Controlled Study","Randomized Controlled Trials","RECRUITING","2026-06-02",{"date":48,"type":49},"2026-06-03","ACTUAL",{"date":51,"type":49},"2025-11-03",{"date":53,"type":22},"2028-11-01",{"name":55,"class":56},"Hospital for Special Surgery, New York","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":79,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":57},"100626579","binaural-beats-for-postoperative-pain-and-anxiety-reduction-100626579","NCT07437469","Binaural Beats for Postoperative Pain and Anxiety Reduction","Binaural Beats vs Music of Choice for Early Postoperative Pain After Ambulatory Total Knee and Total Hip Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists Physical Status Classification System (ASA) 1-3\n* Spinal anesthesia\n* Patients receiving nerve-block in Post-Anesthesia Care Unit (PACU)\n* Primary total hip or total knee arthroplasty\n\nExclusion Criteria:\n\n* Moderate-severe hearing impairment or use of hearing aids\n* History of significant tinnitus, active delirium, chronic high-dose opioid therapy (\\>60 MME\u002Fday baseline)\n* Major psychiatric pathology\n* General anesthesia","99 Years",{"count":67,"type":22},50,[69],"NA","To deliver a 30-minute binaural beats audio intervention in PACU and collect pain and anxiety outcomes immediately following surgery, and 4 hours following surgery completion in adults undergoing ambulatory total knee arthroplasty and total hip arthroplasty (TKA and THA).",[72,73,74,75,76,28,77,78,30],"TKA","THA","Anxiety","Binaural Beats","Music Exposure","Total Knee Arthroplasty","Total Knee Replacement",[73,72,80,81,74,36,75,76],"Total hip arthroplasty","Total knee arthroplasty","2026-04-29",{"date":84,"type":49},"2026-04-30",{"date":86,"type":49},"2026-03-09",{"date":88,"type":22},"2026-08-30",{"name":90,"class":56},"University of Miami",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100629174","dressing-related-experiences-and-surgical-site-self-care-in-hip-and-knee-replacement-an-observational-cohort-study-100629174","NCT07471243","Dressing-related Experiences and Surgical Site Self-care in Hip and Knee Replacement: an Observational Cohort Study","Dressing-Related Experiences and Surgical Site Self-Care in Hip and Knee Replacement: an Observational Cohort Study (DRESS-X)","DRESS-X","Inclusion Criteria:\n\n* Adults (18+) undergoing primary total hip or knee replacement\n* Enrolled in an ERAS protocol\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Requiring revision replacement\n* Unable to provide informed consent (cognitive disorder such as dementia, psychiatric illness)\n* Unable to understand written English",{"count":100,"type":22},100,"OBSERVATIONAL","The goal of this prospective observational cohort study is to investigate dressing-related experiences and surgical site self-care in patients who are undergoing a total hip or knee replacement. The main objectives of the study are:\n\n* To evaluate patient adherence to the ISWCAP self-care checklist after total hip or knee replacement within an ERAS pathway.\n* To explore patient-reported outcomes related to the performance and comfort of advanced dressings.\n* To assess the perceived adequacy and usefulness of post-discharge wound care education.\n* To identify the incidence and types of wound-related complications in the 12 weeks following surgery.\n\nParticipants will give informed consent before surgery and will start the study once the dressing has been applied following surgery. There will be follow up study visits at discharge, 7 days, 12 days, 6 weeks and 12 weeks post-surgery. Data relating to vital signs, medical history, surgery and medication will be taken from routine data.",[30,78],[105,106,107,108,109,110,111,112],"Hip arthroplasty","Hip replacement","Knee arthroplasty","Knee replacement","Musculoskeletal","Enhanced recovery after surgery","ERAS","Surgical wound","NOT_YET_RECRUITING","2026-03-10",{"date":116,"type":49},"2026-03-13",{"date":118,"type":22},"2026-04-01",{"date":120,"type":22},"2027-08-31",{"name":122,"class":56},"Bournemouth University",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":19,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":57},"100534448","effectiveness-of-telerehabilitation-in-continuity-with-outpatient-physiotherapy-after-total-hip-replacement-100534448","NCT06238960","Effectiveness of Telerehabilitation in Continuity With Outpatient Physiotherapy After Total Hip Replacement.","Effectiveness of Telerehabilitation in Continuity With Outpatient Physiotherapy After Total Hip Replacement: Randomized Clinical Trial.","Inclusion Criteria:\n\n* Having undergone total hip replacement surgery (THA)\n* Start outpatient treatment within 7 days of discharge from the Orthopedic Department\n* Age between 50 and 80 years.\n* Continuation of rehabilitation treatments at the IOR Physical Medicine and Rehabilitation service in Argenta.\n* The subjects or any caregivers must be able to use an electronic device (PC, tablet, smartphone).\n\nExclusion Criteria:\n\n* patients undergoing revision of previous prosthesis surgery\n* difficulty understanding the Italian language\u002Flanguage barrier\n* unavailability stable wi-fi connection by the patient","50 Years",{"count":133,"type":22},104,[69],"Total arthroplasty (THA) is the treatment of choice for severe osteoarthritis of the hip joint. Following this type of intervention, a multidisciplinary rehabilitation approach allows you to reduce pain and improve the ability to carry out activities of daily living (ADL), but it is not clear what the optimal rehabilitation program is. Recently, the use of telerehabilitation has increased over the years. Specifically, in treatment of patients following THA surgery, telerehabilitation is able to give similar results to the treatment performed in person terms of pain and function. The aim of this study is to verify whether telerehabilitation associated with In-person treatment is comparable in terms of pain, recovery functionality and patient participation and satisfaction, compared to those provided by rehabilitation alone in the presence of patients undergoing THA surgery.",[30,137,138],"Telerehabilitation","Physiotherapy","2026-02-19",{"date":141,"type":49},"2026-02-23",{"date":143,"type":49},"2024-02-10",{"date":145,"type":22},"2026-12-10",{"name":147,"class":56},"Istituto Ortopedico Rizzoli",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100583568","phase-4-comparing-the-safety-and-effectiveness-of-different-doses-of-morphine-administered-in-spinal-anethesia-for-pain-relief-after-hip-replacement-surgery-100583568","NCT06878014","Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery","Comparison of Safety Profile and Efficacy of Different Doses of Intrathecal Morphine in Total Hip Replacement.","Inclusion Criteria:\n\n* Informed consent to participate in trial\n* Qualification for total hip replacement surgery\n* ASA physical status I-III\n* BMI 19-30\n* Lack of contraindications for drugs and interventions used in trial\n\nExclusion Criteria:\n\n* Incapability to provide informed consent\n* Contraindications for spinal anesthesia\n* Preoperative chronic pain\n* Chronic use of analgesics\n* Obesity (BMI\\>30)\n* Allergies and other contraindications for drugs used in trial\n* Mental or physical incapability to operate PCA syringe pump","75 Years",{"count":157,"type":22},120,[159],"PHASE4","Pain management after total hip replacement is one of the most important aspects of postoperative care for patients and clinicians alike. One of the most common techniques used in anesthesia for this procedure is spinal anesthesia with concurrent administration of opioids into spinal sac. Addition of opioids not only prolongs the anesthesia but also provides pain relief after the procedure for a limited amount of time. Because of its unique chemical properties morphine provides the longest pain relief amongst currently known opioids lasting up to 24 hours. Unfortunately this beneficial effect is associated with both minor and serious adverse effects, most important of which is respiratory depression.\n\nTo limit this potenitialy fatal adverse effect dosing of morphine must be very precise in order to balance advantages and risks.\n\nThe aim of the study was to assess effectiveness and safety profile of different doses of morphine administered during spinal anesthesia for pain control.",[162,163,30,164],"Analgesics, Opioid","Anesthesia, Spinal","Adverse Anesthesia Outcome","2026-02-11",{"date":167,"type":49},"2026-02-12",{"date":169,"type":49},"2025-03-04",{"date":171,"type":22},"2026-06-28",{"name":173,"class":56},"Medical University of Silesia",3,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":19,"enrollmentInfo":182,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":57},"100602183","an-open-label-data-collection-study-of-my-connect-post-op-a-post-operative-communication-tool-100602183","NCT07120191","An Open Label Data Collection Study of My Connect Post-Op, a Post-Operative Communication Tool","Inclusion Criteria:\n\nOrthopedic patients scheduled for elective joint arthroplasty (single or double knee, or single or double hip replacement surgery).\n\nAge 22-80 years. Owns a smart phone. Speaks and understands written and spoken English. Ability to give written informed consent.\n\nExclusion Criteria:\n\nKnown diagnosis of a psychiatric disorder. Known opioid dependence in the Investigator's opinion that may complicate participation.\n\nParticipation in another clinical trial investigating a drug, medical device, or a medical procedure in the 30 days preceding trial inclusion and throughout the duration of the trial.\n\nAny condition that in the Investigator's opinion may complicate or preclude the subject from participating in this trial, such as physical impairment or noncooperation","22 Years",{"count":183,"type":22},200,"This open label, multi-center study will collect data from the participant's use of My Connect Post-Op Software as a post-operative communication solution in supporting patient recovery through Technology-Assisted Conversation (TAC). The application will be tested by patients who have undergone total joint replacement as a post-op communication tool. Data will be collected on how effectively the product guides patients through their recovery, identifying potential complications, and providing appropriate recommendations based on structured question pairs.",[30,78],[187,188,189,190],"Total joint replacement","post op communication","AI assisted conversation","artificial intelligence","2025-08-12",{"date":193,"type":49},"2025-08-15",{"date":195,"type":49},"2025-05-01",{"date":197,"type":22},"2025-11-30",{"name":199,"class":200},"Concentra AI, inc","INDUSTRY",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":207,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100564373","post-market-observational-study-of-the-harmony-evolution-implants-and-instruments-100564373","NCT06628336","Post-Market Observational Study of the HARMONY® Evolution Implants and Instruments","Inclusion Criteria:\n\n* Subjects of 18 years of age and older\n* Each subject who is willing to give informed consent\n* Clinically indicated for a Total Hip Replacement\n* Women of childbearing age who are not pregnant and do not expect to become pregnant within 12 months. A pregnancy test should be performed for women of childbearing age\n* Geographically stable and willing to return to the implanting site for all follow-up visits\n\nExclusion Criteria:\n\n* Acute or chronic, local or systemic infection\n* Muscular, neurological, psychological or vascular deficits\n* Poor bone density and quality likely to affect implant stability (severe osteoporosis)\n* Any concomitant condition likely to affect implant integration or function\n* Allergy or hypersensitivity to any of the materials used\n\nSpecific:\n\n• The HARMONY® Evolution Standard stem size 8 shall not be implanted in subjects weighing more than 70 kg.",{"count":208,"type":22},264,"The purpose of this study is to evaluate the safety and performance of the HARMONY® Evolution implants in a series of operated subjects treated in THR.\n\nThe objective is to demonstrate that the evaluated implants are compliant with the state of the art and the performance (PMA score \\> 15 points) \\& safety claims (The expected acceptable revision rate (state of the art with a confidence interval of 95%) is 3% at 3 years, 5% at 5 years, 7% at 7 years and 10% at 10 years).\n\nThe endpoint of this study is to validate the expected performance of the HARMONY® Evolution implants with the PMA score at 10 years and to validate the safety claim with the expected acceptable revision rate at 10 years.",[30],[212,213,214],"HARMONY","THR","Prosthesis","2024-10-03",{"date":217,"type":49},"2024-10-04",{"date":219,"type":49},"2023-10-11",{"date":221,"type":22},"2035-03-11",{"name":223,"class":200},"Symbios Orthopedie SA",5]